Clinical Trials Logo

Radiation Therapy clinical trials

View clinical trials related to Radiation Therapy.

Filter by:

NCT ID: NCT06178861 Active, not recruiting - Breast Cancer Clinical Trials

Effect of Bra Use During Radiotherapy for Breast Cancer Radiotherapy

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

This prospective randomized study investigated the reproducibility of breast shape, radiation dose irradiated to the lungs, heart, dose distribution, patient satisfaction, and treatment toxicity when wearing and not wearing a bra during radiotherapy for patients with breast cancer.

NCT ID: NCT06159335 Recruiting - Radiation Therapy Clinical Trials

18F-FLUC-CEST PET/MR in Patients With Brain Mets

Start date: January 10, 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining. Participants will undergo a single PET/MRI scan, followed by a separate MRI scan with a tracer. Study participation will last about 3 hours.

NCT ID: NCT06132295 Completed - Radiation Therapy Clinical Trials

Adoption of Multiple Strategies to Reduce the Rate of Marker Detachment During Radiotherapy in Patients With Cancer

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Investigators used in-house-designed radiotherapy red and green light markers to distinguish individual measures after the provision of the initial nursing care to participants, added a homemade health education leaflet to collect data via actual observation, and counted the disappearance or fading of participants' body markers

NCT ID: NCT06128863 Recruiting - Immunotherapy Clinical Trials

Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial

EFTISARC-NEO
Start date: July 17, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II single-arm single-stage study evaluating efficacy and safety of pembrolizumab in combination with a soluble LAG-3 protein, eftilagimod alpha (Efti) and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas. This study will determine the pathologic response rate (defined as percentage of tumor hyalinization/fibrosis) to the combination treatment.

NCT ID: NCT06115850 Completed - Anxiety Clinical Trials

Effect of Music Intervention on Anxiety in Cancer Patients Undergoing Initial Radiation Therapy

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

This prospective randomized trial evaluated the effect of music interventions on anxiety and nervousness during 10 consecutive days in individuals undergoing their first radiation therapy session.

NCT ID: NCT05914142 Completed - Solid Tumor Clinical Trials

Study on the Safety and Effectiveness of Varian ProBeam Proton Therapy Equipment in the Treatment of Solid Tumors

Start date: December 15, 2022
Phase: N/A
Study type: Interventional

This study is a clinical trial of prospective, single-arm objective performance criteria. This trial will be conducted in clinical trial sites with a total of 47 subjects enrolled. All of subjects will be treated with radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam), aim to compare the data with objective performance criteria (OPC) to evaluate the effectiveness and safety of ProBeam radiotherapy system for oncology patients, providing a clinical basis for the medical device registration.

NCT ID: NCT05821452 Not yet recruiting - Chemotherapy Clinical Trials

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Start date: May 25, 2023
Phase: Phase 2
Study type: Interventional

The investigators conducted a phase II, prospective, two-arm clinical study to explore the efficacy of Camrelizumab combined with chemotherapy versus chemoradiotherapy for conversion therapy of potentially resectable advanced esophageal squamous cell carcinoma. This study will provide more evidence for conversion treatment of initially unresectable locally advanced esophageal squamous cell carcinoma and contribute to the development of treatment guidelines for esophageal cancer.

NCT ID: NCT05817201 Recruiting - Esophageal Cancer Clinical Trials

Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

Start date: July 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to explore the therapeutic efficacy of immune checkpoint inhibitors combined with radical radiotherapy in elderly patients with esophageal cancer.

NCT ID: NCT05808998 Not yet recruiting - Radiation Therapy Clinical Trials

A Single-center Observational Clinical Trial of Stereotactic Radiotherapy on Metastatic Spinal Tumors Using TomoTherapy

SM-SBRT
Start date: April 1, 2023
Phase:
Study type: Observational

A single-center observational clinical trial will be performed for metastatic spinal tumors by stereotactic radiotherapy using TomoTherapy. In this study, we will explore the local control rate (LCR), disease-free progression time (PFS), overall survival time (OS), and pain relief in patients with spinal metastasis, so as to provide a basis for developing relevant guidelines or consensus.

NCT ID: NCT05743569 Recruiting - Clinical trials for Head and Neck Cancer

3D Specimen Maps for RT Planning

Start date: January 26, 2023
Phase:
Study type: Observational

The primary objective of this study is to measure the impact of patient-specific 3D specimen maps on adjuvant radiation treatment volumes and doses to critical organs. All patients will receive standard-of-care post-operative radiotherapy not impacted by the experimental 3D specimen maps. The secondary objective is to demonstrate the feasibility of incorporating 3D specimen mapping tools into post-operative communication, and to determine if utilization of the 3D specimen map improves post-operative communication between surgeons, pathologists, and radiation oncologists.